The latest UK peptide medicine news — Mounjaro, Ozempic, retatrutide and NHS policy updates, tracked and explained in plain English as they happen.
A landmark systematic review published in the BMJ in July 2026 compared 19 obesity medicines across 262 clinical trials. According to the BMJ, tirzepatide and CagriSema produced the largest estimated weight reductions. However, injectable semaglutide currently holds the strongest evidence for reducing deaths, heart attacks and kidney disease. The findings are reshaping how clinicians and…
The launch of Wegovy tablets in UK pharmacies was a significant moment for people seeking weight loss treatment. But according to regulators and pharmacists, counterfeit Wegovy pills are already circulating through unregulated online sellers. This pattern is not new. It happens after almost every major medicine launch in the UK. Understanding why it happens and…
Superdrug launched oral semaglutide in the UK in July 2026, becoming the first provider to offer the Wegovy pill commercially following regulatory sign-off from the MHRA. Eligible patients can now access the treatment through an online clinical assessment via Superdrug’s health platform, without needing an injection. According to LADbible, experts are calling this the start…
Eli Lilly, the American pharmaceutical giant behind Mounjaro, has confirmed it intends to launch its oral weight loss pill in Europe and the United Kingdom within the next 12 to 18 months. According to Reuters, the company made this announcement in June 2026 as part of a broader strategic shift towards tablet-based obesity treatments. This…
A genuinely new type of weight loss medicine is making its way through the UK approval process. Orforglipron, branded as Foundayo and made by pharmaceutical company Eli Lilly, is an oral once-daily pill that activates the same hunger-regulating system as Ozempic and Mounjaro — but it is not a peptide and does not require an…
The UK’s medicines regulator has approved a daily weight loss tablet for the first time. The Wegovy pill — an oral version of the drug semaglutide — has been given the green light for adults with obesity. Private prescriptions are expected to be available within weeks. This development was announced on 11 June 2026. According…
A large-scale UK survey has found that households containing a Mounjaro or Wegovy user save an average of £418 per year on grocery bills compared to what they would otherwise have spent. The research adds important new context to the cost conversation around weight loss injections — a conversation that matters to millions of British…
A new experimental drug called apitegromab could help people taking Mounjaro preserve more muscle while losing weight, according to research published in Nature Medicine and reported by BBC News in June 2026. The six-month study followed 102 adults taking Mounjaro. Participants who also received apitegromab retained significantly more lean muscle mass than those receiving a…
Britain is about to approve the world’s first oral semaglutide weight loss pill. The Medicines and Healthcare products Regulatory Agency (MHRA) — the UK body that approves medicines — is expected to give the green light within days. According to the Daily Mail, reporting in June 2026, the decision is imminent and could transform access…
A weight loss injection has just posted the most impressive clinical trial results ever recorded for a medicine in this class. Retatrutide phase 3 results, published on 21 May 2026 from the TRIUMPH-1 trial, show an average body weight loss of 28.3 percent over 80 weeks on the highest dose [Eli Lilly / ClinicalTrials.gov, May…